Open Access

Analysis of efficacy, safety and prognostic factors of DAC‑HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia

  • Authors:
    • Liang Wang
    • Chun Li
    • Fang Xu
    • Fang Cao
    • Bo Zhang
    • Jing Wang
    • Shen Wang
    • Li Chen
    • Na Li
    • Chenglin Liao
    • Hongjun Liu
  • View Affiliations

  • Published online on: November 1, 2021     https://doi.org/10.3892/mco.2021.2431
  • Article Number: 269
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hematopoietic stem cell transplantation (HSCT) is generally considered as the only effective treatment for children with relapsed/refractory (R/R) acute myeloid leukemia (AML). Achieving remission prior to HSCT affects the efficacy of the procedure and patient survival; therefore, induction therapy in children with R/R AML prior to HSCT is very important. The aim of the present study was to evaluate the clinical efficacy, prognosis and safety of 5‑aza‑2‑deoxycytidine (DAC) combined with homoharringtonine + cytarabine + aclarubicin (HAA regimen) in the treatment of pediatric R/R AML. A total of 53 pediatric patients with R/R AML, aged 1‑14 years, were treated with DAC‑HAA. The overall response rate was 83.1%, with a complete remission rate of 77.4% and a partial remission rate of 5.7%. In conclusion, DAC‑HAA therapy for children with R/R AML was found to be associated with a high remission rate, a short period of bone marrow suppression and a good safety profile. Therefore, DAC‑HAA may be of value as a transitional regimen prior to HSCT and is worthy of clinical consideration.
View Figures
View References

Related Articles

Journal Cover

December-2021
Volume 15 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang L, Li C, Xu F, Cao F, Zhang B, Wang J, Wang S, Chen L, Li N, Liao C, Liao C, et al: Analysis of efficacy, safety and prognostic factors of DAC‑HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia. Mol Clin Oncol 15: 269, 2021
APA
Wang, L., Li, C., Xu, F., Cao, F., Zhang, B., Wang, J. ... Liu, H. (2021). Analysis of efficacy, safety and prognostic factors of DAC‑HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia. Molecular and Clinical Oncology, 15, 269. https://doi.org/10.3892/mco.2021.2431
MLA
Wang, L., Li, C., Xu, F., Cao, F., Zhang, B., Wang, J., Wang, S., Chen, L., Li, N., Liao, C., Liu, H."Analysis of efficacy, safety and prognostic factors of DAC‑HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia". Molecular and Clinical Oncology 15.6 (2021): 269.
Chicago
Wang, L., Li, C., Xu, F., Cao, F., Zhang, B., Wang, J., Wang, S., Chen, L., Li, N., Liao, C., Liu, H."Analysis of efficacy, safety and prognostic factors of DAC‑HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia". Molecular and Clinical Oncology 15, no. 6 (2021): 269. https://doi.org/10.3892/mco.2021.2431